Patented microfluidic platform for intact CTC harvest
Capture and harvest circulating tumor cells (CTCs) from cancer patient blood for user-validated analysis.
Benefits of the Parsortix PC1 System
Speak to us about how the Parsortix PC1 System could benefit your laboratory
Contact usLiquid biopsy is an emerging approach to cancer management that provides repeatable access to a tumour sample without the need for an invasive, and potentially dangerous solid tissue biopsy procedure.1
Download brochure Product intended useContact us to discuss how the Parsortix PC1 system can help with your laboratory’s liquid biopsy needs
Contact us
The current National Comprehensive Cancer Network (NCCN) Guidelines for the treatment of metastatic breast cancer (MBC) patients require a tissue biopsy of the metastatic site to support clinical decision-making. Cancer is a dynamic disease that changes over time and there is a clear need for up-to-date information on disease status.2
Despite being recommended in the NCCN Guidelines, many patients are not eligible for biopsy as a result of patients being too sick for the invasive procedure, the inaccessibility of the metastatic site or other organ-specific complications associated with the procedure.3,4
The ability to monitor and analyse CTCs may transform the treatment of MBC, providing patients with personalised cancer care through a non-invasive, repeat liquid biopsy with the power of Parsortix® technology.
“As a breast cancer surgeon, I am very enthusiastic about the potential of liquid biopsy. Our pilot data shows that potentially the same information can be obtained from a simple blood test using the Parsortix® system as from an invasive tissue biopsy and indeed may be advantageous over invasive tissue biopsies in regard to the diverse sites of metastatic disease.”
Julie E. Lang
Chief of Breast Surgery, Cleveland Clinic. Formerly, Director, USC Breast Cancer Program, Associate Professor of Surgery, Norris Comprehensive Cancer Center, University of Southern California
References
- Cortés-Hernández LE, Eslami-S Z, Alix-Panabières C. Liquid Biopsy to Detect Circulating Tumor Cells: Is It Ready for a Value Proposition in Laboratory Medicine?. The Journal of Applied Laboratory Medicine. 2020 Sep;5(5):1027-37. NCCN Clincial Practice Guidelines in Oncology (NCCN Guidelines®), Breast Cancer. Version 2.2022, December 20, 2021.
- Carlson RW, et al, Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network. 2012 Jul 1;10(7):821-9
- Criscitiellio C, et al. Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives. Breast Cancer Res 2014; 16(2):205-12
- Ring A, et al. Circulating Tumor Cell Transcriptomics as Biopsy Surrogates in Metastatic Breast Cancer. Annals of surgical oncology. 2022 May;29(5):2882-94.